Table 1.
Demographics and characteristics of patients enrolled in this study
| Characteristics | Total | CH | LC | HCC |
P-value |
||
| CH vs LC | CH vs HCC | LC vs HCC | |||||
| n (%) | 179 (100.0) | 64 (35.8) | 65 (36.3) | 50 (27.9) | - | - | - |
| Gender (male/female) (% male) | 129/50 (72.1) | 38/26 (59.4) | 47/18 (72.3) | 44/6 (88.0) | 0.121 | < 0.001 | 0.040 |
| Age (yr, mean ± SD) | 45.8 ± 12.3 | 39.7 ± 13.3 | 49.9 ± 10.8 | 48.4 ± 9.5 | < 0.001 | < 0.001 | 0.495 |
| AFP [ng/mL, median (min-max)] | 13.2 (0.1-3 295 000.0) | 3.2 (0.1-5039.0) | 11.8 (1.0-444 718.0) | 704.8 (1.2-3 295 000.0) | < 0.001 | < 0.001 | < 0.001 |
| AST [IU/L, median (min-max)] | 66.0 (7.0-3618.0) | 39.5 (7.0-481.0) | 66.0 (15.0-297.0) | 138.0 (9.0-3618.0) | < 0.001 | < 0.001 | < 0.001 |
| ALT [IU/L, median (min-max)] | 50.0 (1.0-860.0) | 47 (6-748) | 46 (9-216) | 64 (1-860) | 0.480 | 0.481 | 0.123 |
| AST/ALT | 1.28 (0.1-120.6) | 0.9 (0.1-2.9) | 1.4 (0.2-6.0) | 2.1 (0.1-120.6) | < 0.001 | < 0.001 | < 0.001 |
| Serum HBV DNA (log10 IU/mL, mean ± SD) | 5.6 ± 2.0 | 6.1 ± 2.1 | 5.8 ± 1.4 | 4.6 ± 2.2 | 0.334 | < 0.001 | 0.003 |
| All HBeAg(+), (%) | 71 (39.7) | 36 (56.3) | 19 (29.2) | 16 (32.0) | 0.002 | 0.010 | 0.749 |
| All HBeAg(-), (%) | 108 (60.3) | 28 (43.8) | 46 (70.8) | 34 (68.0) | |||
| HBeAg(+); HBeAb(-), (%) | 71 (39.7) | 36 (56.3) | 19 (29.2) | 16 (32.0) | 0.002 | 0.010 | 0.749 |
| HBeAg(-); HBeAb(+), (%) | 86 (48.0) | 22 (34.4) | 40 (61.5) | 24 (48.0) | 0.002 | 0.141 | 0.039 |
| HBeAg(-); HBeAb(-), (%) | 22 (12.3) | 6 (9.4) | 6 (9.2) | 10 (20.0) | 0.978 | 0.105 | 0.098 |
| Genotype | |||||||
| B, n (%) | 132 (73.7) | 47 (73.4) | 48 (73.8) | 37 (74.0) | 0.958 | 0.946 | 0.985 |
| C, n (%) | 47 (26.3) | 17 (26.6) | 17 (26.2) | 13 (26.0) | |||
CH: Chronic hepatitis; LC: Liver cirrhosis; HCC: Hepatocellular carcinoma; AFP: α-fetoprotein; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; HBeAb: Hepatitis B e antibody.